- 专利标题： Use of ureidomustine (BO-1055) in cancer treatment
-
申请号： US15745639申请日： 2016-08-17
-
公开(公告)号： US10548861B2公开(公告)日： 2020-02-04
- 发明人: Malcolm Moore , Jae-Hung Shieh , Tsann-Long Su , Te-Chang Lee
- 申请人： Academia Sinica , Memorial Sloan Kettering Cancer Center
- 申请人地址： TW Nankang, Taipei US NY New York
- 专利权人： Academia Sinica,Memorial Sloan Kettering Cancer Center
- 当前专利权人： Academia Sinica,Memorial Sloan Kettering Cancer Center
- 当前专利权人地址： TW Nankang, Taipei US NY New York
- 代理机构： Wood, Phillips, Katz, Clark & Mortimer
- 国际申请： PCT/US2016/047264 WO 20160817
- 国际公布： WO2017/031156 WO 20170223
- 主分类号： A61K31/167
- IPC分类号： A61K31/167 ; A61K31/17 ; A61K45/06 ; A61P35/02
摘要：
Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.
公开/授权文献
- US20190008808A1 Use of Ureidomustine (BO-1055) in Cancer Treatment 公开/授权日：2019-01-10
信息查询
